Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

ATNM Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Actinium Pharmaceuticals, Inc.AMEX: ATNM

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit remains negative

Q2 FY2026 gross profit was $35M, compared with $0 a year earlier. Trailing-twelve-month gross profit was $35.49M. Over 3 fiscal years it compounded at -55.6% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near $35M or moves back toward the trailing-twelve-month quarterly average of $8.87M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$35M+16009.1% QoQ
Last fiscal yearDec 2025
$90K+111.1% YoY
LTMJun 2026
$35.49M+8840.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+111.1%——
3-year CAGR-55.6%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
90K USD
Year-over-year change
+111.1%
4-year CAGR
-38.3%

Gross Profit vs competitors

How ATNM compares with its peers on the latest reported figures

  • ATNM's LTM Jun 2026 gross profit of $35.49M is the 2nd highest of the 5 companies compared; the peer median is $0.
  • Its year-over-year change of +8840.1% is the highest of 4, against a peer median of +100.0%.
  • Gross profit amounts to 101.1% of revenue for ATNM, versus a peer median of 70.7%.
ATNM Competitors Peer median
Gross Profit for ATNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XLOXilio Therapeutics, Inc.LTM Mar 2026$37.81M +307.7%—70.7%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$35.49M +8840.1%-55.6%101.1%
PDSBPDS Biotechnology CorporationLTM Mar 2026$0 +100.0%——
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 ———
OKUROnKure Therapeutics, Inc.LTM Mar 2026-$203K -1591.7%——
Peer median (excluding ATNM) $0+100.0%—70.7%

Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.14M1.03M81K090K
Cost of Revenue524K00811K0
Gross Profit620K1.03M81K(811K)90K
Gross Margin54.2%100.0%100.0%—100.0%
Research & Development17.51M23.14M38.67M30.05M21.12M
Selling, General & Admin8.08M12M13.33M12.08M15.21M
Operating Expenses25.58M35.13M52M41.31M36.34M
Depreciation & Amortization524K699K790K811K821K
EBITDA(24.25M)(32.32M)(48.03M)(37.43M)(33.07M)
EBITDA Margin-2119.8%-3137.7%-59293.8%—-36740.0%
Operating Income(24.96M)(34.1M)(51.92M)(42.12M)(36.25M)
Operating Margin-2182.2%-3311.1%-64098.8%—-40274.4%
Interest Income190K1.09M3.1M3.88M2.36M
Interest Expense00000
Other Income / Expenses190K1.09M3.1M3.88M2.36M
Income Before Tax(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Pre-Tax Margin-2165.6%-3205.5%-60269.1%—-37652.2%
Income Tax Expense00000
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Net Margin-2165.6%-3205.5%-60269.1%—-37652.2%
EPS (Basic)(1.20)(1.37)(1.83)(1.27)(1.09)
EPS (Diluted)(1.20)(1.37)(1.83)(1.27)(1.09)
Weighted Avg Shares20.57M24.14M26.6M30.07M31.2M
Weighted Avg Shares (Diluted)20.57M24.14M26.6M30.07M31.2M

Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Intrinsic Alpha fair value

Locked

Current Price

$1.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.